"The sign was first formally described by Wada et al. in 2007 1, but the phenomenon was recognised much earlier on conventional angiographic studies performed on intracerebral haemorrhage patients in the pre-CT era 3."
"Trials of haemostatic therapy, e.g. recombinant activated factor VII (SPOTLIGHT and STOP-IT) and tranexamic acid (STOP-AUST), in patients with intracerebral haemorrhage have utilised the 'spot sign' to identify patients who are most likely to benefit from therapy. They have, however, so far failed to demonstrate a clear benefit from either therapy although this may be due to timing of therapy 7,8."
"Trials of haemostatic therapy, e.g. recombinant activated factor VII (SPOTLIGHT and STOP-IT) and tranexamic acid (STOP-AUST), in patients with intracerebral haemorrhage have utilised the 'spot sign' to identify patients who are most likely to benefit from therapy. They have, however, so far failed to demonstrate a clear benefit from either therapy although this may be due to timing of therapy 7,8."
"Trials of haemostatic therapy, e.g. recombinant activated factor VII (SPOTLIGHT and STOP-IT) and tranexamic acid (STOP-AUST), in patients with intracerebral haemorrhage have utilised the 'spot sign' to identify patients who are most likely to benefit from therapy. They have, however, so far failed to demonstrate a clear benefit from either therapy although this may be due to timing of therapy 7,8."
"The spot sign generally defined as a unifocal region of contrast enhancement resulting in focal increased density compared to the surrounding haematoma on CT angiography. The shape is not important and it can be spherical, linear or branching."
"The spot sign should not be confused with the dot sign consisting of a hyperdense thrombus within an artery seen in cross-section (e.g. MCA branches within the Sylvian fissure on axial imaging)."
"The spot sign can potentially be seen in any intracerebral haemorrhage, however, is more likely to be seen earlier on. For example, of those patients scanned within 6 hours of symptom onset, about 30% will demonstrate the spot sign 2. This will depend, however, on the technique used; higher in dynamic CTA and lower in delayed CTA."
"calcification: choroid plexus, pineal gland, granuloma; thus it is important to ensure it is not hyperdense on non-contrast CT"